Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age

Influenza and other Respiratory Viruses

Volumn 4, Issue 3, 2010, Pages 141-145

  Belshe, Robert B ^a   Toback, Seth L ^b   Yi, Tingting ^b   Ambrose, Christopher S ^b  

^a SAINT LOUIS UNIVERSITY   (United States)

^b MEDIMMUNE   (United States)

Author keywords

Influenza; Live attenuated influenza vaccine; Trivalent inactivated influenza vaccine

Indexed keywords

INFLUENZA VACCINE; LIVE VACCINE; PLACEBO;

ADOLESCENT; AGE DISTRIBUTION; ANTIGENICITY; ARTICLE; CHILD; CHILD CARE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; INFANT; INFLUENZA; PRESCHOOL CHILD; PRIORITY JOURNAL; SAMPLE SIZE; SCHOOL CHILD; VIRUS STRAIN;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINES, ATTENUATED;

EID: 77953071901     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/j.1750-2659.2009.00124.x     Document Type: Article

References (28)

1. Ashkenazi S, Vertruyen A, Aristegui J. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006, 25:870-879.
2. Rhorer J, Ambrose CS, Dickinson S. Efficacy of live attenuated influenza vaccine in children: a meta-analysis of nine randomized clinical trials. Vaccine 2009, 27:1101-1110.
3. Belshe RB, Edwards KM, Vesikari T. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356:685-696.
4. Belshe RB, Gruber WC, Mendelman PM. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000, 136:168-175.
5. Belshe RB, Mendelman PM, Treanor J. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998, 338:1405-1412.
6. Bracco H, Farhat CK, Tregnaghi MW. Efficacy and safety of one and two doses of live attenuated influenza vaccine in vaccine-naive children. Pediatr Infect Dis J 2009, 28:365-371.
7. Fleming DM, Crovari P, Wahn U. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006, 25:860-869.
8. Forrest BD, Pride MW, Dunning AJ. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008, 15:1042-1053.
9. Lum LCS, Forrest BD. Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. Vaccine 2009, 10.1016/j.vaccine.2009.11.054, DOI
10. Tam JS, Capeding MR, Lum LC. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J 2007, 26:619-628.
11. Vesikari T, Fleming DM, Aristegui JF. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics 2006, 118:2298-2312.
12. Hawksworth AW, Russell KL, Faix DJ. Effectiveness of the 2006-2007 influenza vaccine: data from US military basic training centers [Abstract P725]. 2007, 6th Meeting of the Options for Control of Influenza Diseases, 17-23 June, Toronto, ON, Canada
13. Hawksworth AW, Russell KL, Strickler JK, Gaydos JC, Malone JL, Ryan MAK. Effectiveness of the 2004-2005 influenza vaccine: data from US military basic training centers [Abstract 1012]. 2005, 43rd Annual Meeting of IDSA, 6-9 October, San Francisco, CA
14. Treanor JJ, Kotloff K, Betts RF. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 1999, 18:899-906.
15. Ohmit SE, Victor JC, Rotthoff JR. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006, 355:2513-2522.
16. Strickler JK, Hawksworth AW, Myers C, Irvine M, Ryan MA, Russell KL. Influenza vaccine effectiveness among US military basic trainees, 2005-06 season. Emerg Infect Dis 2007, 13:617-619.
17. Monto AS, Ohmit SE, Petrie JG. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009, 361:1260-1267.
18. Wang Z, Tobler S, Roayaei J, Eick A. Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel. JAMA 2009, 301:945-953.
19. Eick AA, Wang Z, Hughes H, Ford SM, Tobler SK. Comparison of the trivalent live attenuated vs. inactivated influenza vaccines among U.S. military service members. Vaccine 2009, 27:3568-3575.
20. 2006, Data on File, Gaithersburg, MD, MedImmune, Inc
21. Piedra PA, Gaglani MJ, Kozinetz CA. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics 2007, 120:e553-e564.
22. Belshe RB, Gruber WC, Mendelman PM. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000, 181:1133-1137.
23. Block SL, Reisinger KS, Hultquist M, Walker RE. Comparative immunogenicities of frozen and refrigerated formulations of live attenuated influenza vaccine in healthy subjects. Antimicrob Agents Chemother 2007, 51:4001-4008.
24. Block SL, Yogev R, Hayden FG, Ambrose CS, Zeng W, Walker RE. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine 2008, 26:4940-4946.
25. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972, 70:767-777.
26. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979, 35:69-75.
27. Potter CW, Jennings R, Nicholson K, Tyrrell DA, Dickinson KG. Immunity to attenuated influenza virus WRL 105 infection induced by heterologous, inactivated influenza A virus vaccines. J Hyg (Lond) 1977, 79:321-332.
28. Nichol KL, Mendelman PM, Mallon KP. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999, 282:137-144.